Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Theratechnologies Inc
T.TH
Alternate Symbol(s):
THTX
Healthcare
Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs...
in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:TH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(54)
•••
PWIB123
X
View Profile
View Bullboard History
Comment by
PWIB123
on Nov 26, 2024 10:54am
RE:RE:RE:New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Never in my life have I seen a company so bad at public communication.
(54)
•••
PWIB123
X
View Profile
View Bullboard History
Comment by
PWIB123
on Nov 26, 2024 10:53am
RE:RE:New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Nope. You heard correctly. They have set a precedence that we cannot trust a word that comes out of their mouth. Even if they simply provided interim updates, that would enhance
...more
(54)
•••
PWIB123
X
View Profile
View Bullboard History
Comment by
PWIB123
on Nov 26, 2024 10:49am
RE:RE:RE:New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
I'm feeling the same sense of frustration as you. I remember reading that this new formula really won't help sales, but am I recalling correctly that it will help extend the patent
...more
(27)
•••
Joemare
X
View Profile
View Bullboard History
Comment by
Joemare
on Nov 26, 2024 8:54am
RE:RE:New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
10 months to reply to a submission they thought was a walk in the park. It means they had to redo many of what was required. Anyways, at least they pushed it out before they fiscal
...more
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on Nov 26, 2024 8:46am
RE:RE:New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
If the same applies to our Egrifta shortage we'll be out of our investment money in 10 months and IQ will own the company. They'll probably celebrate with the C-Suite and linkedin the
...more
(201)
•••
palinc2000
X
View Profile
View Bullboard History
Comment by
palinc2000
on Nov 26, 2024 8:35am
RE:New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
In January 2024 they said that they would swifly adress the concerns of FDA .. that was 10 mos ago Maybe the delay is normal but why did they create the illusion that they had all the answers? I
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 26, 2024 7:30am
New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Resubmission addresses questions raised in January 2024 Complete Response LetterF8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophyMONTREAL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc...
read article.
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on Nov 25, 2024 8:00pm
RE:RE:20 Working days left to give us something tangible
This might sound supid but Egrifta is manufactured in Canada.. will it be taxed 25% like the rest of exports.
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on Nov 25, 2024 2:53pm
RE:20 Working days left to give us something tangible
Anyway otherwise tax selling will take care of wathevers left of our investment. We're all sick of waiting for the next thing to happen... it's been 30 years for gods sake. Death
...more
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on Nov 25, 2024 9:44am
RE:20 Working days left to give us something tangible
Stay tuned for mind boggling deal closed from a strength position.
(27)
•••
Joemare
X
View Profile
View Bullboard History
Post by
Joemare
on Nov 25, 2024 9:21am
20 Working days left to give us something tangible
20 days left to give us Egrifta production and F8 update. Th108 update. Partnership ?? ---- accreditive acquisition update -Yeah right! These guys are phony phony phony 'executives'.
...more
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on Nov 25, 2024 8:07am
RE:RE:RE:RE:RE:Winning with partnerships
And maybe facing another one if they can't get Egrifta manufacturing back up before too long. They could keep a year of inventory in case of problem. It's part of the problem in
...more
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on Nov 24, 2024 2:40pm
RE:RE:RE:RE:Winning with partnerships
They are glorifying a reverse 10 bagger and secondarie issues at 25 cents. It's an insult to anyone except Investissement Qubec that got 20% of the company for nothing... giveaway, nada, zero.
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on Nov 24, 2024 2:36pm
RE:RE:RE:Winning with partnerships
Last time 8 saw a partnership it was for Trogarzo with Taimed and Serono to buy back the wrights for Egrifta... Luc Tanguay was the CEO. now since our savior arrived 5 years ago many
...more
(197)
•••
scarlet1967
X
View Profile
View Bullboard History
Comment by
scarlet1967
on Nov 23, 2024 4:04pm
RE:RE:Winning with partnerships
https://insights.citeline.com/authors/david-wild/ I believe so as in his other publications there are often quotes from the respective executives of the companies and the company he works for offer
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
One Property, One Focus on Advancing this Gold Project in Ontario